Next urgent steps include an integration of the LRP12 epigenetic test into the Network Genomic Medicine (NGM) Lung Cancer platform, Europe’s largest platform for molecular testing, to improve the accuracy of the prediction of platin therapy resistance and a transfer into clinical applications. This evidence concerns the gene LRP12 and lung cancer.